Tempest Therapeutics Inc (TPST) Stock Analysis

AI analysis of Tempest Therapeutics Inc (TPST)

Sell

Tempest Therapeutics Inc (TPST) is not a good buy right now. The current price is $0.3801, which is significantly lower than the 52-week high of $10.33, indicating a drastic decline of 96.12% over the past year. Additionally, the RSI is at a very low 10.575, suggesting extreme oversold conditions, but this could reflect deeper underlying issues rather than a buying opportunity. The company has reported a net income loss of $27,696,000 for Q1 2026, which raises concerns about its financial stability. The recent financing news has not positively impacted the stock, as it fell 4.60% after announcing a private placement to raise $2.5 million, reflecting market skepticism about its future prospects. The main risk is the company's ongoing losses and reliance on external funding, which could further dilute shareholder value.

Valuation Metrics

The current forward P/E ratio for Tempest Therapeutics Inc (TPST) is 0.00, compared to its 5-year average forward P/E of -1.06.

Forward P/E

Overvalued

5Y Average P/E

-1.06

Current P/E

0.00

Overvalued

-0.32

Undervalued

-1.80

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.48

Current EV/EBITDA

0.00

Overvalued

0.34

Undervalued

-1.30

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Alphio AI Price Scenarios for TPST

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TPST

$7.28

Scenario price

B

Base

Base · 50%TPST

$6.05

Scenario price

B

Bear

Bear · 25%TPST

$5.75

Scenario price

TPST FAQ — answered by Alphio AI

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tempest Therapeutics Inc (TPST) is not a good buy right now. The current price is $0.3801, which is significantly lower than the 52-week high of $10.33, indicating a drastic decline of 96.12% over the past year. Additionally, the RSI is at a very low 10.575, suggesting extreme oversold conditions, but this could reflect deeper underlying issues rather than a buying opportunity. The company has reported a net income loss of $27,696,000 for Q1 2026, which raises concerns about its financial stability. The recent financing news has not positively impacted the stock, as it fell 4.60% after announcing a private placement to raise $2.5 million, reflecting market skepticism about its future prospects. The main risk is the company's ongoing losses and reliance on external funding, which could further dilute shareholder value.